Loading
A phase 2 trial of sacituzumab govitecan and bevacizumab in triple-negative breast cancer, run by YING FAN, now recruiting.
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC is a phase 2, interventional study registered as NCT07359404 by YING FAN, with a registry enrolment figure of 60 participants, started 2024-04-01 and due to reach its primary completion in 2026-12-31. Interventions recorded: Sacituzumab Govitecan (SG); Bevacizumab. Conditions listed: Advanced Breast Cancer. Triple-negative eligibility wording from the registry: "Pathologically confirmed recurrent or metastatic Triple-Negative Breast Cancer (TNBC)". Sites: China. No results are recorded here; the registry entry is the source.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.
Shares Sacituzumab govitecan, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Antibody-drug conjugate (ADC) and the tag tnbc-deep-dive.